51
|
Abstract
Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. Transgenic plant technology is attractive for vaccine development because these vaccines are needle-less, stable, and easy to administer. This chapter examines some early human studies of oral transgenic plant-derived vaccines against enterotoxigenic Escherichia coli infection, norovirus, and hepatitis B.
Collapse
Affiliation(s)
- Alexander V. Karasev
- grid.266456.50000000122849900Department of Plant, Soil & Entomological Sciences, University of Idaho, Moscow, ID 83844-2339 USA
| |
Collapse
|
52
|
Seo JK, Lee HG, Kim KH. Systemic gene delivery into soybean by simple rub-inoculation with plasmid DNA of a Soybean mosaic virus-based vector. Arch Virol 2008; 154:87-99. [PMID: 19096905 DOI: 10.1007/s00705-008-0286-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2008] [Accepted: 11/17/2008] [Indexed: 10/21/2022]
Abstract
Plant virus-based vectors provide attractive and valuable tools for conventional transgenic technology and gene function studies in plants. In the present study, we established the infectivity of intact plasmid DNA of Soybean mosaic virus (SMV) cDNA upon simple rub-inoculation of soybean leaves by utilizing viral transcription and processing signals to produce infectious in vivo transcripts. Furthermore, we engineered this SMV cDNA clone as a gene delivery vector for systemic expression of foreign proteins in soybean. Using this SMV-based vector, several genes with different biological activities were successfully expressed and stably maintained following serial plant passage in soybean. Thus, DNA-mediated gene delivery using this SMV-based vector provides a rapid and cost-effective approach for the overproduction of valuable proteins and for the evaluation of new traits in soybean after simple rub-inoculation onto leaves.
Collapse
Affiliation(s)
- Jang-Kyun Seo
- Department of Agricultural Biotechnology, College of Agriculture and Life Sciences, Seoul National University, Seoul, South Korea
| | | | | |
Collapse
|
53
|
Ohki S, Dohi K, Tamai A, Takeuchi M, Mori M. Stable-isotope labeling using an inducible viral infection system in suspension-cultured plant cells. JOURNAL OF BIOMOLECULAR NMR 2008; 42:271-7. [PMID: 18937031 DOI: 10.1007/s10858-008-9283-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2008] [Accepted: 09/30/2008] [Indexed: 05/11/2023]
Abstract
We established a novel strategy for preparing uniformly stable isotope-labeled proteins by using suspension-cultured plant cells and an inducible virus vector encoding the research target. By using this new method, we demonstrated the expression of three proteins, namely, Escherichia coli dihydrofolate reductase (DHFR), chicken calmodulin (CaM), and porcine protein kinase C-dependent protein phosphatase-1 inhibitor with a molecular mass of 17-kDa (CPI-17). In addition, we successfully expressed bovine pancreatic trypsin inhibitor (BPTI), which contains three pairs of disulfide bonds, as the soluble form. In the most efficient case, as little as 50 ml culture yielded 3-4 mg (15)N-labeled protein suitable for NMR experiments. The (1)H-(15)N HSQC spectra of all of these proteins clearly indicated that their structures were identical to those of their counterparts reported previously. Thus, the present results suggest that our novel protocol is a potential method for NMR sample preparation.
Collapse
Affiliation(s)
- Shinya Ohki
- Japan Advanced Institute of Science and Technology, Center for Nano Materials and Technology, Nomi, Ishikawa, Japan.
| | | | | | | | | |
Collapse
|
54
|
Ji JE, Lee JM, Choi JM, Choi YH, Kim EK, Chu SJ, Kim SK, Ahn KH, Lee DH, Kim HH, Han K, Kim DK. Subcutaneous Four-Week Repeated Dose Toxicity Studies of Rice Cell-Derived Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Rats. Toxicol Res 2008; 24:315-320. [PMID: 32038810 PMCID: PMC7006265 DOI: 10.5487/tr.2008.24.4.315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2008] [Revised: 11/05/2008] [Accepted: 11/06/2008] [Indexed: 11/20/2022] Open
Abstract
Recombinant human granulocyte-macrophage colony stimulating factor (hGM-CSF) is a glycoprotein and hematopoietic growth factors that regulates the proliferation of myeloid precursor cells and activates mature granulocytes and macrophages. In a previous study, we reported that hGM-CSF could be produced in transgenic rice cell suspension culture, termed rhGM-CSF. In the present study, we examined the repeated dose toxicity of rhGM-CSF in SD rats. The repeated dose toxicity study was performed at each dose of 50 and 200 µg/kg subcutaneous administration of rhGM-CSF everyday for 28-days period. The results did not show any changes in food and water intake. There were also no significant changes in both body and organ weights between the control and the tested groups. The hematological and blood biochemical parameters were statistically not different in all groups. These results suggest that rhGM-CSF may show no repeated dose toxicity in SD rats under the conditions.
Collapse
Affiliation(s)
- Jung Eun Ji
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Jung Min Lee
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Jong Min Choi
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Young Hwa Choi
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Eun Kyung Kim
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - So Jung Chu
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Seok Kyun Kim
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Kyong Hoon Ahn
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Dong Hoon Lee
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Ha Hyung Kim
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| | - Kyuboem Han
- Department of Environmental & Health Chemistry, Hanson Biotech Co., Ltd., Daejeon, 305-811 Korea
| | - Dae Kyong Kim
- Department of Environmental & Health Chemistry, Physical Pharmacy Laboratory, College of Pharmacy, Chung-Ang University, Seoul, 156-756 Korea
| |
Collapse
|
55
|
Ribeiro CW, Soares-Costa A, Falco MC, Chabregas SM, Ulian EC, Cotrin SS, Carmona AK, Santana LA, Oliva MLV, Henrique-Silva F. Production of a His-tagged canecystatin in transgenic sugarcane and subsequent purification. Biotechnol Prog 2008; 24:1060-6. [DOI: 10.1002/btpr.45] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
56
|
Pires AS, Cabral MG, Fevereiro P, Stoger E, Abranches R. High levels of stable phytase accumulate in the culture medium of transgenic Medicago truncatula cell suspension cultures. Biotechnol J 2008; 3:916-23. [PMID: 18446871 DOI: 10.1002/biot.200800044] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The use of plants for production of recombinant proteins is becoming widely accepted. More recently, plant cell cultures have been proposed as valuable systems for producing a wide range of biologically active proteins. Such systems provide certain advantages over whole plants, but yields are still considered a limitation. In this study we established a Medicago truncatula cell suspension line expressing phytase from Aspergillus niger. Phytase is an N-glycosylated enzyme that breaks down indigestible phytate, resulting in an increased availability of phosphorus and other minerals in monogastric animals and reduced levels of phosphorus output in their manure. Various production systems have previously been used to express heterologous phytase, including several plant species. In this work, remarkable amounts of enzymatically active recombinant phytase were produced and secreted into the culture medium. Recombinant phytase accumulated to at least 25 mg/L and remained stable along the growth curve, and an enriched fraction with high enzymatic activity was easily obtained. We therefore propose M. truncatula cell suspension cultures as a potential system for the production of recombinant proteins. Most importantly, we have shown that, contrary to general belief, it is possible to achieve high levels of a functional recombinant protein in plant cell culture systems.
Collapse
Affiliation(s)
- Ana Sofia Pires
- Plant Cell Biology Laboratory, Instituto de Tecnologia Quimica e Biologica, UNL, Oeiras, Portugal
| | | | | | | | | |
Collapse
|
57
|
Oszvald M, Kang TJ, Tomoskozi S, Jenes B, Kim TG, Cha YS, Tamas L, Yang MS. Expression of Cholera Toxin B Subunit in Transgenic Rice Endosperm. Mol Biotechnol 2008; 40:261-8. [DOI: 10.1007/s12033-008-9083-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2008] [Accepted: 06/18/2008] [Indexed: 11/28/2022]
|
58
|
Abstract
Global demand for recombinant proteins has steadily accelerated for the last 20 years. These recombinant proteins have a wide range of important applications, including vaccines and therapeutics for human and animal health, industrial enzymes, new materials and components of novel nano-particles for various applications. The majority of recombinant proteins are produced by traditional biological "factories," that is, predominantly mammalian and microbial cell cultures along with yeast and insect cells. However, these traditional technologies cannot satisfy the increasing market demand due to prohibitive capital investment requirements. During the last two decades, plants have been under intensive investigation to provide an alternative system for cost-effective, highly scalable, and safe production of recombinant proteins. Although the genetic engineering of plant viral vectors for heterologous gene expression can be dated back to the early 1980s, recent understanding of plant virology and technical progress in molecular biology have allowed for significant improvements and fine tuning of these vectors. These breakthroughs enable the flourishing of a variety of new viral-based expression systems and their wide application by academic and industry groups. In this review, we describe the principal plant viral-based production strategies and the latest plant viral expression systems, with a particular focus on the variety of proteins produced and their applications. We will summarize the recent progress in the downstream processing of plant materials for efficient extraction and purification of recombinant proteins.
Collapse
Affiliation(s)
- Chiara Lico
- UTS BIOTEC, Section of Genetics and Plant Genomics, ENEA CR Casaccia, Rome, Italy
| | | | | |
Collapse
|
59
|
Kim HJ, Lee DH, Kim DK, Han GB, Kim HJ. The Glycosylation and in Vivo Stability of Human Granulocyte-Macrophage Colony-Stimulating Factor Produced in Rice Cells. Biol Pharm Bull 2008; 31:290-4. [DOI: 10.1248/bpb.31.290] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
60
|
Kim HJ, Kim HJ. The glycosylation and pharmacokinetics of CTLA4Ig produced in rice cells. Biol Pharm Bull 2007; 30:1913-7. [PMID: 17917261 DOI: 10.1248/bpb.30.1913] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cytotoxic T-lymphocyte antigen 4-immunoglobulin (CTLA4Ig) has immunosuppressive activity and the ability to induce immune tolerance. There has been no report of its glycosylation ratio or of the role of its glycans. We investigated the terminal sialylation of rice cell-derived recombinant human CTLA4Ig (rrhCTLA4Ig) using lectins. The glycosylation ratios of rrhCTLA4Ig and Chinese hamster ovary (CHO) cell-derived recombinant human CTLA4Ig (crhCTLA4Ig) were evaluated by chemical deglycosylation. After intravenous (i.v.) or subcutaneous (s.c.) administration to rats, the pharmacokinetics of rrhCTLA4Ig and crhCTLA4Ig as well as of their deglycosylated forms were evaluated. rrhCTLA4Ig does not have terminal sialic acids and its glycosylation ratio was slightly lower than that of crhCTLA4Ig. Its terminal elimination half-life (T(1/2)) was shorter than that of crhCTLA4Ig following i.v. administration. However, the half-life was significantly prolonged and was similar with that of crhCTLA4Ig following s.c. administration. Moreover, the deglycosylated forms of both preparations were cleared from the circulation faster than the native forms. These results suggest that the presence of glycans on rrhCTLA4Ig and crhCTA4Ig are important for their in vivo stability. In addition, the glycan structure of rrhCTLA4Ig is more effective in maintaining in vivo stability after s.c. administration than after i.v. administration although the glycans on rrhCTLA4Ig lack terminal sialic acids, suggesting that its glycans have the potential for in vivo stability.
Collapse
Affiliation(s)
- Hyoung Jin Kim
- College of Pharmacy, Chung-Ang University, Seoul, South Korea
| | | |
Collapse
|
61
|
Sivakumar G. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots. Biotechnol J 2007; 1:1419-27. [PMID: 17136730 DOI: 10.1002/biot.200600117] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Plants are the richest source for different bioactive molecules. Because of the vast number of side effects associated with synthetic pharmaceuticals, medical biotechnologists turned to nature to provide new promising therapeutic molecules from plant biofactories. The large-scale availability of the disease- and pesticide-free raw material is, however, restricted in vivo. Many bioactive plant secondary metabolites are accumulated in roots. Engineered plants can also produce human therapeutic proteins. Vaccines and diagnostic monoclonal antibodies can be won from their roots, so that engineered plants hold immense potential for the biopharmaceutical industry. To obtain sufficient amounts of the plant bioactive molecules for application in human therapy, adventitious and hairy roots have to be cultured in in vitro systems. High-tech pilot-scale bioreactor technology for the establishment of a long-term adventitious root culture from biopharmaceutical plants has recently been established. In this review, I briefly discuss a technology for cultivating bioactive molecule-rich adventitious and hairy roots from plants using a high-tech bioreactor system, as well as the principles and application of genome-restructuring mechanisms for plant-based biopharmaceutical production from roots. High-tech bioreactor-derived bioactive phytomolecules and biopharmaceuticals hold the prospect of providing permanent remedies for improving human well-being.
Collapse
|
62
|
Takagi H, Hirose S, Yasuda H, Takaiwa F. Biochemical safety evaluation of transgenic rice seeds expressing T cell epitopes of Japanese cedar pollen allergens. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2006; 54:9901-5. [PMID: 17177518 DOI: 10.1021/jf061848v] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
UNLABELLED Transgenic rice seeds, which express a hybrid peptide comprising seven predominant human T cell epitopes (7Crp) derived from Japanese cedar pollen allergens, have been shown to function as an effective edible vaccine for the control of pollen allergen-induced responses. In this study, we characterized biochemical properties of transgenic seeds expressing the 7Crp peptide. The levels of chemical compositions, such as carbohydrate, protein, lipid, amino acid, fatty acid, mineral, and vitamin, were substantially equivalent between transgenic 7Crp and its nontransgenic counterpart seeds. The contents of three major allergenic proteins in transgenic seeds were not enhanced by expression of the 7Crp peptide when compared with those of nontransgenic seeds. The 7Crp peptide expressed in seeds was susceptible to simulated gastric/intestinal fluids. N-Glycosylation was not observed in the 7Crp peptide sequence. These results indicate that transgenic 7Crp seeds are substantially equivalent to nontransgenic parental seeds except for the presence of the 7Crp peptide. KEYWORDS Food safety assessment; transgenic rice seed; edible vaccine; peptide-based immunotherapy; Japanese cedar pollinosis.
Collapse
Affiliation(s)
- Hidenori Takagi
- Transgenic Crop Research and Development Center, National Institute of Agrobiological Sciences, 2-1-2 Kannondai, Tsukuba, Ibaraki 305-8602, Japan
| | | | | | | |
Collapse
|
63
|
Dohi K, Nishikiori M, Tamai A, Ishikawa M, Meshi T, Mori M. Inducible virus-mediated expression of a foreign protein in suspension-cultured plant cells. Arch Virol 2006; 151:1075-84. [PMID: 16421635 DOI: 10.1007/s00705-005-0705-8] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2005] [Accepted: 12/05/2005] [Indexed: 12/20/2022]
Abstract
Although suspension-cultured plant cells have many potential merits as sources of useful proteins, the lack of an efficient expression system has prevented using this approach. In this study, we established an inducible tomato mosaic virus (ToMV) infection system in tobacco BY-2 suspension-cultured cells to inducibly and efficiently produce a foreign protein. In this system, a modified ToMV encoding a foreign protein as replacement of the coat protein is expressed from stably transformed cDNA under the control of an estrogen-inducible promoter in transgenic BY-2 cells. Estrogen added to the culture activates an estrogen-inducible transactivator expressed constitutively from the transgene and induces transcription and replication of viral RNA. In our experiments, accumulation of viral RNA and expression of green fluorescent protein (GFP) encoded in the virus were observed within 24 h after induction. The amount of GFP reached approximately 10% of total soluble protein 4 d after induction. In contrast, neither viral RNA nor GFP were detected in uninduced cells. The inducible virus infection system established here should be utilized not only for the expression of foreign proteins, but also for investigations into the viral replication process in cultured plant cells.
Collapse
Affiliation(s)
- K Dohi
- Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan
| | | | | | | | | | | |
Collapse
|
64
|
Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 2006; 10:185-218. [PMID: 15757412 DOI: 10.1517/14728214.10.1.185] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Many of our 'small-molecule-drugs' are natural products from plants, or are synthetic compounds based on molecules found naturally in plants. However, the vast majority of the protein therapeutics (or biopharmaceuticals) we use are from animal or human sources, and are produced commercially in microbial or mammalian bioreactor systems. Over the last few years, it has become clear that plants have great potential for the production of human proteins and other protein-based therapeutic entities. Plants offer the prospect of inexpensive biopharmaceutical production without sacrificing product quality or safety, and following the success of several plant-derived technical proteins, the first therapeutic products are now approaching the market. In this review, the different plant-based production systems are discussed and the merits of transgenic plants are evaluated compared with other platforms. A detailed discussion is provided of the development issues that remain to be addressed before plants become an acceptable mainstream production technology. The many different proteins that have already been produced using plants are described, and a sketch of the current market and the activities of the key players is provided. Despite the currently unclear regulatory framework and general industry inertia, the benefits of plant-derived pharmaceuticals are now bringing the prospect of inexpensive veterinary and human medicines closer than ever before.
Collapse
Affiliation(s)
- Richard M Twyman
- University of York, Department of Biology, Heslington, York, YO10 5DD, UK.
| | | | | |
Collapse
|
65
|
Takagi H, Hiroi T, Yang L, Tada Y, Yuki Y, Takamura K, Ishimitsu R, Kawauchi H, Kiyono H, Takaiwa F. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci U S A 2005; 102:17525-30. [PMID: 16278301 PMCID: PMC1297655 DOI: 10.1073/pnas.0503428102] [Citation(s) in RCA: 173] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Peptide immunotherapy using multiple predominant allergen-specific T cell epitopes is a safe and promising strategy for the control of type I allergy. In this study, we developed transgenic rice plants expressing mouse dominant T cell epitope peptides of Cry j I and Cry j II allergens of Japanese cedar pollen as a fusion protein with the soybean seed storage protein glycinin. Under the control of the rice seed storage protein glutelin GluB-1 promoter, the fusion protein was specifically expressed and accumulated in seeds at a level of 0.5% of the total seed protein. Oral feeding to mice of transgenic rice seeds expressing the T cell epitope peptides of Cry j I and Cry j II before systemic challenge with total protein of cedar pollen inhibited the development of allergen-specific serum IgE and IgG antibody and CD4(+) T cell proliferative responses. The levels of allergen-specific CD4(+) T cell-derived allergy-associated T helper 2 cytokine production of IL-4, IL-5, and IL-13 and histamine release in serum were significantly decreased. Moreover, the development of pollen-induced clinical symptoms was inhibited in our experimental sneezing mouse model. These results indicate the potential of transgenic rice seeds in production and mucosal delivery of allergen-specific T cell epitope peptides for the induction of oral tolerance to pollen allergens.
Collapse
Affiliation(s)
- Hidenori Takagi
- Plant Biotechnology Department, National Institute of Agrobiological Sciences, Tsukuba, Ibaraki 305-8602, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
66
|
Hull AK, Yusibov V, Mett V. Inducible expression in plants by virus-mediated transgene activation. Transgenic Res 2005; 14:407-16. [PMID: 16201407 DOI: 10.1007/s11248-005-0388-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
We have developed a plant virus-mediated transgene activation (VMTA) system that utilizes a viral expression vector to present the inducer. The concept was tested using two well characterized components: (i) an artificial promoter based on the yeast GAL4 upstream activating sequence and the minimal TATA element of Cauliflower Mosaic Virus 35S RNA promoter, and (ii) a transcriptional activator (TA) consisting of a fusion between the GAL4 DNA binding domain and the Herpes simplex virus VP16 activation domain. The TA was expressed under the control of the subgenomic promoter of a Tobacco Mosaic Virus-based expression vector. The VMTA system was functional in transient Agroinfiltration assays with the reporter gene beta-glucuronidase, the intracellular domain of the diabetes associated autoimmune antigen, IA-2ic, and with the anti-tetanus antibody 9F12. Transgenic lines harboring the reporter gene were also examined. The VMTA system displayed tight transcriptional control in both transient assays and in transgenic Nicotiana benthamiana plants carrying the TA-inducible reporter.
Collapse
Affiliation(s)
- Anna K Hull
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware 19711, USA
| | | | | |
Collapse
|
67
|
Karnoup AS, Turkelson V, Anderson WHK. O-Linked glycosylation in maize-expressed human IgA1. Glycobiology 2005; 15:965-81. [PMID: 15901675 DOI: 10.1093/glycob/cwi077] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
O-Linked glycans vary between eukaryotic cell types and play an important role in determining a glycoprotein's properties, including stability, target recognition, and potentially immunogenicity. We describe O-linked glycan structures of a recombinant human IgA1 (hIgA1) expressed in transgenic maize. Up to six proline/hydroxyproline conversions and variable amounts of arabinosylation (Pro/Hyp + Ara) were found in the hinge region of maize-expressed hIgA1 heavy chain (HC) by using a combination of matrix-assisted laser-desorption ionization mass spectrometry (MALDI MS), chromatography, and amino acid analysis. Approximately 90% of hIgA1 was modified in this way. An average molar ratio of six Ara units per molecule of hIgA1 was revealed. Substantial sequence similarity was identified between the HC hinge region of hIgA1 and regions of maize extensin-family of hydroxyproline-rich glycoproteins (HRGP). We propose that because of this sequence similarity, the HC hinge region of maize-expressed hIgA1 can become a substrate for posttranslational conversion of Pro to Hyp by maize prolyl-hydroxylase(s) with the subsequent arabinosylation of the Hyp residues by Hyp-glycosyltransferase(s) in the Golgi apparatus in maize endosperm tissue. The observation of up to six Pro/Hyp hydroxylations combined with extensive arabinosylation in the hIgA1 HC hinge region is well in agreement with the Pro/Hyp hydroxylation model and the Hyp contiguity hypothesis suggested earlier in literature for plant HRGP. For the first time, the extensin-like Hyp/Pro conversion and O-linked arabinosylation are described for a recombinant therapeutic protein expressed in transgenic plants. Our findings are of significance to the field of plant biotechnology and biopharmaceutical industry-developing transgenic plants as a platform for the production of recombinant therapeutic proteins.
Collapse
Affiliation(s)
- Anton S Karnoup
- Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, MI 48667, USA.
| | | | | |
Collapse
|
68
|
Abstract
Transgenic plant-derived vaccines offer a new strategy for the development of safe, inexpensive vaccines against diarrhoeal diseases. In animal and Phase I clinical studies, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. This review examines some early attempts to develop oral transgenic plant vaccines against enteric infections such as enterotoxigenic Escherichia coli infection, cholera and norovirus infection.
Collapse
Affiliation(s)
- Carol O Tacket
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21202, USA.
| |
Collapse
|
69
|
Abstract
Transgenic plants present a novel system for both production and oral delivery of vaccine antigens. Production of protein antigen in food plants is substantially cheaper than production in bacterial, fungal, insect cell, or mammalian cell culture. Edible plants themselves can also serve as the oral vaccine delivery system. Phase-1 studies of raw transgenic potatoes expressing the B subunit of Escherichia coli heat labile enterotoxin (LT-B), potatoes expressing Norwalk virus capsid protein, and defatted corn germ meal expressing LT-B have been conducted. New oral vaccines based on other transgenic plants will soon be evaluated in humans.
Collapse
Affiliation(s)
- Carol O Tacket
- Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St., Baltimore, MD 21201, USA.
| |
Collapse
|
70
|
Schillberg S, Twyman RM, Fischer R. Opportunities for recombinant antigen and antibody expression in transgenic plants—technology assessment. Vaccine 2005; 23:1764-9. [PMID: 15734038 DOI: 10.1016/j.vaccine.2004.11.002] [Citation(s) in RCA: 102] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Plants are now gaining widespread acceptance as a general platform for the large-scale production of recombinant proteins. The principle has been demonstrated by the success of a diverse repertoire of proteins, with therapeutic molecules showing the most potential for added value. Over the past 10 years, several efficient plant-based expression systems have emerged. However, a number of issues remain to be addressed before plant bioreactors can be accepted and adopted widely in preference to the established microbial and mammalian platforms. Overcoming bottlenecks imposed by low yields, poor and inconsistent product quality and difficulties with downstream processing are the most important goals for researchers working in this field. The achievement of these goals is conditional on the development of extraction and processing steps that comply with GMP standards, including extensive quality assurance and control procedures. Such rigorous and validated standards should be combined with measures applied earlier in production to ensure product sustainability and quality, such as the use of master seed banking procedures. Moreover, there are several further challenges concerning topics of environmental impact, biosafety and risk assessment, which reflect the release of transgenic plants, as well the safety of the plant-derived products themselves. We are facing a growing demand for protein diagnostics and therapeutics, but lack the capacity to meet those demands using established facilities. A shift to plant bioreactors may, therefore, become necessary within the next few years, making it more imperative that the technical and regulatory limitations are addressed and solved. The production of pharmaceutical proteins in plants will only realize its huge potential if the products are provided at consistent high quality levels, allowing the delivery of clinical grade proteins that will gain regulatory approval and which can be used routinely in clinical trials.
Collapse
Affiliation(s)
- Stefan Schillberg
- Fraunhofer-Institute for Molecular Biology and Applied Ecology, Worringerweg 1, 52074 Aachen, Germany.
| | | | | |
Collapse
|
71
|
Sugita K, Endo-Kasahara S, Tada Y, Lijun Y, Yasuda H, Hayashi Y, Jomori T, Ebinuma H, Takaiwa F. Genetically modified rice seeds accumulating GLP-1 analogue stimulate insulin secretion from a mouse pancreatic beta-cell line. FEBS Lett 2005; 579:1085-8. [PMID: 15710395 DOI: 10.1016/j.febslet.2004.12.082] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2004] [Revised: 12/17/2004] [Accepted: 12/17/2004] [Indexed: 11/25/2022]
Abstract
Glucagon-like peptide-1 (7-36) amide (GLP-1) is the most potent physiological insulinotropic hormone in humans. We produced large amounts of a GLP-1 analogue, [Ser8, Gln26, Asp34]-GLP-1, which is resistant to trypsin-digestion, as part of a chimeric rice seed storage protein, a 26 kDa globulin, in genetically modified rice seeds. Junction sites between GLP-1 analogue and globulin were replaced by tryptic cleavage sites. The highest level of GLP-1 analogue accumulation was approximately 20-50 microg per seed. We found that GLP-1 analogue derived from trypsin-digested genetically modified rice seeds stimulated insulin secretion from a mouse pancreatic beta-cell line, MIN6.
Collapse
Affiliation(s)
- Koichi Sugita
- Forestry Science Laboratory, Nippon Paper Industries Co., Ltd., 5-21-1, Oji, Kita-ku, Tokyo 114-0002, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Future Applications of GMOs. GENES ON THE MENU 2005. [PMCID: PMC7120976 DOI: 10.1007/3-540-27136-8_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
73
|
Chen M, Liu X, Wang Z, Song J, Qi Q, Wang PG. Modification of plant N-glycans processing: The future of producing therapeutic protein by transgenic plants. Med Res Rev 2005; 25:343-60. [PMID: 15499575 DOI: 10.1002/med.20022] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Transgenic plants are regarded as one of the most promising systems for the production of human therapeutic proteins. The number of therapeutic proteins successfully produced in plants is steadily arising. However, the glycoproteins normally produced from plants are not the same as native therapeutic proteins produced from mammals or humans. In addition to in vitro enzymatic modeling glycoproteins, there are two gene manipulation strategies to humanize plant N-glycans connected to the glycoproteins. One is retaining the recombinant glycoproteins in endoplasmic reticulum (ER), the site where few specific modifications of N-glycans occurs. The other is inhibiting the plant endogenous Golgi glycosyltransferase and/or adding new glycosyltransferase from mammalians. In this review, the biosynthesis of N-glycans in plants, the modification of the plant N-glycans processing will be discussed.
Collapse
Affiliation(s)
- Min Chen
- The State Key Laboratory of Microbial Technology, School of Life Science, Shandong University, Jinan, Shandong 250100, P.R. China
| | | | | | | | | | | |
Collapse
|
74
|
Abstract
Modern biotechnology has resulted in a resurgence of interest in the production of new therapeutic agents using botanical sources. With nearly 500 biotechnology products approved or in development globally, and with production capacity limited, the need for efficient means of therapeutic protein production is apparent. Through genetic engineering, plants can now be used to produce pharmacologically active proteins, including mammalian antibodies, blood product substitutes, vaccines, hormones, cytokines, and a variety of other therapeutic agents. Efficient biopharmaceutical production in plants involves the proper selection of host plant and gene expression system, including a decision as to whether a food crop or a non-food crop is more appropriate. Product safety issues relevant to patients, pharmaceutical workers, and the general public must be addressed, and proper regulation and regulatory oversight must be in place prior to commercial plant-based biopharmaceutical production. Plant production of pharmaceuticals holds great potential, and may become an important production system for a variety of new biopharmaceutical products.
Collapse
Affiliation(s)
- D A Goldstein
- Monsanto Company A2NE, 800 N. Lindbergh Blvd, St Louis, MO 63167, USA.
| | | |
Collapse
|
75
|
Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotechnol 2004; 21:570-8. [PMID: 14624867 DOI: 10.1016/j.tibtech.2003.10.002] [Citation(s) in RCA: 358] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Richard M Twyman
- Department of Biology, University of York, Heslington, York YO10 5DD, UK.
| | | | | | | | | |
Collapse
|
76
|
Nguyen HT, Leelavathi S, Reddy VS. Bacteriophage T7 RNA polymerase-directed, inducible and tissue-specific over-expression of foreign genes in transgenic plants. PLANT BIOTECHNOLOGY JOURNAL 2004; 2:301-10. [PMID: 17134391 DOI: 10.1111/j.1467-7652.2004.00071.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
A widely applicable bacteriophage T7 RNA polymerase-directed, tissue-specific and inducible over-expression of foreign genes in transgenic plants was developed. This was achieved through the simultaneous transformation of a modified T7 RNA polymerase to specifically transcribe the foreign gene placed under the control of T7 expression signals. The T7 RNA polymerase recognized the chimeric uidA gene integrated randomly into tobacco and rice genomes. Results from the use of six different promoters with different tissue specificities indicated that the recombinant protein was expressed at a several-fold (3-10-fold) higher level when compared with transgenes expressed directly under the control of these tissue-specific promoters. An important feature of the T7 system in plants was the near-uniform expression in the independently transformed plants, in contrast with the large variations observed in transgene expression under the direct control of plant promoters. In addition, our results demonstrated the application of the T7 system in the regulation of transgene expression through chemically inducible mechanisms. This versatility of controlled and regulated expression offers a powerful tool that could be used in various programmes in plant biotechnology and genomic studies.
Collapse
Affiliation(s)
- Huu Tam Nguyen
- International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067, India
| | | | | |
Collapse
|
77
|
Teli NP, Timko MP. Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals. PLANT CELL, TISSUE AND ORGAN CULTURE 2004; 79:125-145. [PMID: 32214567 PMCID: PMC7089434 DOI: 10.1007/s11240-004-0653-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.
Collapse
Affiliation(s)
- Nilesh P Teli
- Department of Biology, University of Virginia, Gilmer Hall 044, VA USA
| | - Michael P Timko
- Department of Biology, University of Virginia, Gilmer Hall 044, VA USA
| |
Collapse
|
78
|
Shah MM, Fujiyama K, Flynn CR, Joshi L. Sialylated endogenous glycoconjugates in plant cells. Nat Biotechnol 2003; 21:1470-1. [PMID: 14608367 DOI: 10.1038/nbt912] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2003] [Accepted: 09/09/2003] [Indexed: 11/08/2022]
Abstract
Bioengineered plants are emerging as promising systems for the production of therapeutically valuable proteins. It has been commonly accepted that plants do not perform mammalian-like post-translational modifications, particularly sialylation of glycoconjugates, and no evidence has previously been reported to suggest that they have such capabilities. Here we report the presence of sialylated glycoconjugates in suspension-cultured cells of Arabidopsis thaliana and suggest that a genetic and enzymatic basis for sialylation exists in plants.
Collapse
Affiliation(s)
- Miti M Shah
- Harrington Department of Bioengineering and Arizona BioDesign Institute, Arizona State University, PO Box 879709, Tempe, Arizona 85287-9709, USA
| | | | | | | |
Collapse
|
79
|
Ma JKC, Drake PMW, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003; 4:794-805. [PMID: 14526375 DOI: 10.1038/nrg1177] [Citation(s) in RCA: 465] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Imagine a world in which any protein, either naturally occurring or designed by man, could be produced safely, inexpensively and in almost unlimited quantities using only simple nutrients, water and sunlight. This could one day become reality as we learn to harness the power of plants for the production of recombinant proteins on an agricultural scale. Molecular farming in plants has already proven to be a successful way of producing a range of technical proteins. The first plant-derived recombinant pharmaceutical proteins are now approaching commercial approval, and many more are expected to follow.
Collapse
Affiliation(s)
- Julian K-C Ma
- Department of Infectious Diseases, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK.
| | | | | |
Collapse
|
80
|
Ribela MTCP, Gout PW, Bartolini P. Synthesis and chromatographic purification of recombinant human pituitary hormones. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 790:285-316. [PMID: 12767339 DOI: 10.1016/s1570-0232(03)00125-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Recombinant DNA-derived proteins and, in particular, human pituitary hormones, are increasingly used for research, diagnostic and therapeutic purposes. This trend has demanded new synthetic approaches and improved purification techniques. The type and sequence of the purification steps have to be selected in accordance with the cloning and protein expression strategy, the host organism and cellular localization of the protein of interest, with a view to producing the desired product at a required purity, biological activity and acceptable cost. This review article describes and analyzes the main synthetic and purification strategies that have been used for the production of recombinant human growth hormone, prolactin, thyrotropin, luteinizing hormone and follicle-stimulating hormone, giving special consideration to the few published downstream processes utilized by the biotechnology industry. Practically all types of prokaryotic and eukaryotic organisms utilized for this purpose are also reviewed.
Collapse
Affiliation(s)
- Maria Teresa C P Ribela
- Biotechnology Department, IPEN-CNEN, Travessa R 400, Cidade Universitária, 05508-900, São Paulo, Brazil.
| | | | | |
Collapse
|
81
|
Abstract
BACKGROUND Food biotechnology represents advancement in the traditional interspecies and intergeneric breeding methods for improving food supplies worldwide. With respect to safety, foods developed through biotechnology techniques represent one of the most extensively reviewed agricultural advancements in history. OBJECTIVE To review the relevant issues with respect to foods from genetically modified crops and allergenicity. DATA SOURCES To impart this information, the author will rely upon his experiences with investigations into food allergy and food allergens, participation in various workshops designed to determine allergenicity of novel proteins introduced into the diet, web sites, issue papers, and articles relevant to the topic. RESULTS Given that there are no validated methods or models to determine potential allergenicity of novel proteins, criteria have been established based upon characteristics of known food allergens. The combination of genetic and bioinformatics information available from known food allergens applied to foods developed from genetically modified crops to avoid the inadvertent introduction of allergens into foods should pose no significant allergenic concern to individuals with a genetic predisposition to food allergy. Education and sound scientific evaluation provided to the consumer should alleviate any fear of emotionalism as implied by "Frankenfoods." CONCLUSIONS The estimation that more than two trillion transgenic plants have been grown in 1999 and 2000 alone, with no overt documented adverse food reactions being reported, indicates that genetic modification through biotechnology will not impose immediate significant risks as food allergen sources beyond that of our daily dietary intake of foods from crop plants.
Collapse
Affiliation(s)
- Ricki M Helm
- Arkansas Children's Hospital Research Institute, Little Rock, Arkansas 72202-3591, USA.
| |
Collapse
|
82
|
Tackaberry ES, Prior F, Bell M, Tocchi M, Porter S, Mehic J, Ganz PR, Sardana R, Altosaar I, Dudani A. Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Genome 2003; 46:521-6. [PMID: 12834071 DOI: 10.1139/g03-008] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The use of transgenic plants in the production of recombinant proteins for human therapy, including subunit vaccines, is being investigated to evaluate the efficacy and safety of these emerging biopharmaceutical products. We have previously shown that synthesis of recombinant glycoprotein B (gB) of human cytomegalovirus can be targeted to seeds of transgenic tobacco when directed by the rice glutelin 3 promoter, with gB retaining critical features of immunological reactivity (E.S. Tackaberry et al. 1999. Vaccine, 17: 3020-3029). Here, we report development of second generation transgenic plant lines (T1) homozygous for the transgene. Twenty progeny plants from two lines (A23T(1)-2 and A24T(1)-3) were grown underground in an environmentally contained mine shaft. Based on yields of gB in their seeds, the A23T(1)-2 line was then selected for scale-up in the same facility. Analyses of mature seeds by ELISA showedthat gB specific activity in A23T(1)-2 seeds was over 30-fold greater than the best T0 plants from the same transformation series, representing 1.07% total seed protein. These data demonstrate stable inheritance, an absence of transgene inactivation, and enhanced levels of gB expression in a homozygous second generation plant line. They also provide evidence for the suitability of using this environmentally secure facility to grow transgenic plants producing therapeutic biopharmaceuticals.
Collapse
Affiliation(s)
- Eilleen S Tackaberry
- Centre for Biologics Research, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, ON K1A 0L2, Canada.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
83
|
Avesani L, Falorni A, Tornielli GB, Marusic C, Porceddu A, Polverari A, Faleri C, Calcinaro F, Pezzotti M. Improved in planta expression of the human islet autoantigen glutamic acid decarboxylase (GAD65). Transgenic Res 2003; 12:203-12. [PMID: 12739888 DOI: 10.1023/a:1022947726557] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The smaller isoform of the enzyme glutamic acid decarboxylase (GAD65) is a major islet autoantigen in autoimmune type 1 diabetes mellitus (T1DM). Transgenic plants expressing human GAD65 (hGAD65) are a potential means of direct oral administration of the islet autoantigen in order to induce tolerance and prevent clinical onset of disease. We have previously reported the successful generation of transgenic tobacco and carrot that express immunoreactive, full-length hGAD65. In the present study, we tested the hypothesis that the expression levels of recombinant hGAD65 in transgenic plants can be increased by targeting the enzyme to the plant cell cytosol and by mediating expression through the potato virus X (PVX) vector. By substituting the NH2-terminal region of hGAD65 with a homologous region of rat GAD67, a chimeric GAD67(1-87)/GAD65(88-585) molecule was expressed in transgenic tobacco plants. Immunolocalization analysis showed that immunoreactive GAD67/65 was found in the plant cell cytosol. By using a radio-immuno assay with human serum from a GAD65 autoantibody-positive T1DM patient, the highest expression level of the recombinant GAD67/65 protein was estimated to be 0.19% of the total soluble protein, compared to only 0.04% of wild-type hGAD65. Transient expression of wild-type, full-length hGAD65 in N. benthamiana mediated by PVX infection was associated with expression levels of immunoreactive protein as high as 2.2% of total soluble protein. This substantial improvement of the expression of hGAD65 in plants paves the way for immunoprevention studies of oral administration of GAD65-containing transgenic plant material in animal models of spontaneous autoimmune diabetes.
Collapse
Affiliation(s)
- Linda Avesani
- Dipartimento Scientifico e Tecnologico, Università degli Studi di Verona, Strada le Grazie 15, 37134, Verona, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
84
|
Su WW, Arias R. Continuous plant cell perfusion culture: Bioreactor characterization and secreted enzyme production. J Biosci Bioeng 2003; 95:13-20. [PMID: 16233360 DOI: 10.1016/s1389-1723(03)80142-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2002] [Accepted: 08/20/2002] [Indexed: 10/27/2022]
Abstract
Culture perfusion is widely practiced in mammalian cell processes to enhance secreted antibody production. Here, we report the development of an efficient continuous perfusion process for the cultivation of plant cell suspensions. The key to this process is a perfusion bioreactor that incorporates an annular settling zone into a stirred-tank bioreactor to achieve continuous cell/medium separation via gravitational sedimentation. From washout experiments, we found that under typical operating conditions (e.g., 200 rpm and 0.3 vvm) the liquid phase in the entire perfusion bioreactor was homogeneous despite the presence of the cylindrical baffle. Using secreted acid phosphatase (APase) produced in Anchusa officinalis cell culture as a model we have studied the perfusion cultures under complete or partial cell retention. The perfusion culture was operated under phosphate limitation to stimulate APase production. Successful operation of the perfusion process over four weeks has been achieved in this work. When A. officinalis cells were grown in the perfusion reactor and perfused at up to 0.4 vvd with complete cell retention, a cell dry weight exceeding 20 g/l could be achieved while secreted APase productivity leveled off at approximately 300 units/l/d. The culture became extremely dense with the maximum packed cell volume (PCV) surpassing 70%. In comparison, the maximum cell dry weight and overall secreted APase productivity in a typical batch culture were 10-12 g/l and 100-150 units/l/d, respectively. Operation of the perfusion culture under extremely high PCV for a prolonged period, however, led to declined oxygen uptake and reduced viability. Subsequently, cell removal via a bleed stream at up to 0.11 vvd was tested and shown to stabilize the culture at a PCV below 60%. With culture bleeding, both specific oxygen uptake rate and viability were shown to increase. This also led to a higher cell dry weight exceeding 25 g/l, and further improvement of secreted APase productivity that reached a plateau fluctuating around 490 units/l/d.
Collapse
Affiliation(s)
- Wei Wen Su
- Department of Molecular Biosciences & Bioengineering, University of Hawaii, Honolulu, HI 96822, USA.
| | | |
Collapse
|
85
|
Hood EE, Woodard SL, Horn ME. Monoclonal antibody manufacturing in transgenic plants--myths and realities. Curr Opin Biotechnol 2002; 13:630-5. [PMID: 12482526 DOI: 10.1016/s0958-1669(02)00351-8] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The number and types of antibodies expressed in plants has increased steadily since the first reports of this accomplishment in the 1980s, illustrating the versatility of plants as a production system for antibodies. Many recent reviews have detailed the antibody forms that have been derived from plant expression systems. This contribution focuses on the remaining challenges to develop plant-derived therapeutic antibodies into products, and some of the progress that is being made in addressing these challenges.
Collapse
Affiliation(s)
- Elizabeth E Hood
- ProdiGene, Inc., 101 Gateway Blvd, Suite 100, College Station, Texas 77845, USA.
| | | | | |
Collapse
|
86
|
Abstract
Many researchers have acknowledged the fact that there exists an immense potential for the application of the cellulose-binding domains (CBDs) in the field of biotechnology. This becomes apparent when the phrase "cellulose-binding domain" is used as the key word for a computerized patent search; more then 150 hits are retrieved. Cellulose is an ideal matrix for large-scale affinity purification procedures. This chemically inert matrix has excellent physical properties as well as low affinity for nonspecific protein binding. It is available in a diverse range of forms and sizes, is pharmaceutically safe, and relatively inexpensive. Present studies into the application of CBDs in industry have established that they can be applied in the modification of physical and chemical properties of composite materials and the development of modified materials with improved properties. In agro-biotechnology, CBDs can be used to modify polysaccharide materials both in vivo and in vitro. The CBDs exert nonhydrolytic fiber disruption on cellulose-containing materials. The potential applications of "CBD technology" range from modulating the architecture of individual cells to the modification of an entire organism. Expressing these genes under specific promoters and using appropriate trafficking signals, can be used to alter the nutritional value and texture of agricultural crops and their final products.
Collapse
Affiliation(s)
- Ilan Levy
- Institute of Plant Science and Genetics in Agriculture and Otto Warburg Centre for Agricultural Biotechnology, Faculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, PO Box 12, Rehovot 76100, Israel
| | | |
Collapse
|
87
|
Craik DJ, Daly NL, Plan MR, Salim AA, Sando L. STRUCTURE AND FUNCTION OF PLANT TOXINS (WITH EMPHASIS ON CYSTINE KNOT TOXINS). ACTA ACUST UNITED AC 2002. [DOI: 10.1081/txr-120014405] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|